Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Harvard Business School
Merck
Colorcon

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for IW-1701

See Plans and Pricing

« Back to Dashboard

What is the drug development status for IW-1701?

IW-1701 is an investigational drug.

There have been 6 clinical trials for IW-1701. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Anemia, Sickle Cell, Esophageal Achalasia, and [disabled in preview]. The leading clinical trial sponsors are Ironwood Pharmaceuticals, Inc. and [disabled in preview].

There are three US patents protecting this investigational drug and twenty-five international patents.

Recent Clinical Trials for IW-1701
TitleSponsorPhase
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy VolunteersIronwood Pharmaceuticals, Inc.Phase 1
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male VolunteersIronwood Pharmaceuticals, Inc.Phase 1
A Study of the Effect of IW-1701, a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)Ironwood Pharmaceuticals, Inc.Phase 2

See all IW-1701 clinical trials

Clinical Trial Summary for IW-1701

Top disease conditions for IW-1701
Top clinical trial sponsors for IW-1701

See all IW-1701 clinical trials

US Patents for IW-1701

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IW-1701   Start Trial sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
IW-1701   Start Trial sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
IW-1701   Start Trial sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IW-1701

Drugname Country Document Number Estimated Expiration Related US Patent
IW-1701 Australia 2014227862 2033-03-15   Start Trial
IW-1701 Australia 2019203606 2033-03-15   Start Trial
IW-1701 Brazil 112015023349 2033-03-15   Start Trial
IW-1701 Canada 2907111 2033-03-15   Start Trial
IW-1701 China 105408328 2033-03-15   Start Trial
IW-1701 China 108912111 2033-03-15   Start Trial
IW-1701 China 109369635 2033-03-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.